SARS-CoV-2 peptide vaccine elicits T-cell responses in mice but does not protect against infection or disease
Baxter, V. K.; Anderson, E. J.; Taft-Benz, S. A.; Olsen, K. S.; Sambade, M.; Gentry, K. M.; Beck, W. A.; Garness, J.; Woods, A.; Fini, M.; Carpenter, B.; Smith, C. C.; Heise, M. T.; Vincent, B. G.; Rubinsteyn, A.
Show abstract
We vaccinated BALB/c mice with peptides derived from the SARS-CoV-2 proteome selected in silico to elicit T-cell responses and/or B-cell responses against linear epitopes. These peptides were administered in combination with either of two adjuvants, poly(I:C) and the STING agonist BI-1387466. Antibody responses against predicted linear epitopes were not observed but both adjuvants consistently elicited T-cell responses to the same peptides, which were primarily from the set chosen for predicted T-cell immunogenicity. The magnitude of T-cell responses was significantly higher with BI-1387466 compared with poly(I:C). Neither adjuvant group, however, provided any protection against infection with the murine adapted virus SARS-CoV-2-MA10 or from disease following infection. In light of more recent evidence for protection from severe disease mediated by CD8+ T-cells, we suspect that the epitopes selected for vaccination were not presented by infected murine cells.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice 96%
- An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits potent immunity after a single dose. 96%
- Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern 96%
Similar papers in this journal
- A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model 96%
- Trivalent SARS-CoV-2 S1 Subunit Protein Vaccination Induces Broad Humoral Responses in BALB/c Mice 95%
- Soluble Spike DNA vaccine provides long-term protective immunity against SAR-CoV-2 in mice and nonhuman primates 95%
Similar papers in this journal
- Virus-like particles (VLPs) are efficient tools for boosting mRNA-induced antibodies 96%
- A TLR4 ligand-based adjuvant for promoting the immunogenicity of Typhoid subunit vaccines 96%
- Addressing SARS-CoV-2 Evolution: Neutralization of Emerging Variants of Concern by the AVX/COVID-12 'Patria' Vaccine Based on HexaPro-S Ancestral Wuhan Spike or Its Updated BA.2.75.2 Version 96%
Similar papers in this journal
- Intranasal Nanoemulsion Adjuvanted S-2P Vaccine Demonstrates Protection in Hamsters and Induces Systemic, Cell-Mediated and Mucosal Immunity in Mice 96%
- Different adjuvanted pediatric HIV envelope vaccines induced distinct plasma antibody responses despite similar B cell receptor repertoires in infant rhesus macaques. 95%
- Immunogenic Amino Acid Motifs and Linear Epitopes of COVID-19 mRNA Vaccines 95%
Similar papers in this journal
- mRNA Vaccines Induce Rapid Antibody Responses in Mice 96%
- mRNA-based vaccine candidate COReNAPCIN(R) induces robust humoral and cellular immunity in mice and non-human primates 95%
- Combination Ad26.RSV.preF/RSV preF protein vaccine induces superior humoral, cellular, and protective immunity compared with individual vaccine components in preclinical models 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.